Literature DB >> 6356280

Clinical study of combination therapy with oxacillin and rifampin for staphylococcal infections.

P Van der Auwera, F Meunier-Carpentier, J Klastersky.   

Abstract

In a prospective, randomized study of staphylococcal infections, 27 patients received oxacillin plus rifampin and 29 received oxacillin alone. Vancomycin was substituted for oxacillin when the pathogen was demonstrated to be resistant to oxacillin in vitro. Infection was cured in 18 (67%) of the 27 patients receiving oxacillin (or vancomycin) plus rifampin and in 12 (41%) of the 29 receiving oxacillin (or vancomycin) alone (P less than .01). The clinical effect of the addition of rifampin to oxacillin (or vancomycin) was beneficial in spite of a rifampin-associated reduction in the bactericidal activity of serum containing high concentrations of oxacillin.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6356280     DOI: 10.1093/clinids/5.supplement_3.s515

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  21 in total

1.  In vitro killing of community-associated methicillin-resistant Staphylococcus aureus with drug combinations.

Authors:  Samuel A Shelburne; Daniel M Musher; Kristina Hulten; Heather Ceasar; Michael Y Lu; Imran Bhaila; Richard J Hamill
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

2.  [Disputed therapy recommendations for infectious endocarditis].

Authors:  W V Kern
Journal:  Internist (Berl)       Date:  2013-09       Impact factor: 0.743

3.  Effect of abscess milieu on bactericidal activity of LY146032 against staphylococci.

Authors:  R E Bryant; J A Mazza; E M Gardner
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

4.  Evaluation of the teichoic acid antibody assay using a commercial antigen.

Authors:  P Van der Auwera; A Mimouna
Journal:  Eur J Clin Microbiol       Date:  1985-12       Impact factor: 3.267

Review 5.  Methicillin-resistant staphylococci.

Authors:  H F Chambers
Journal:  Clin Microbiol Rev       Date:  1988-04       Impact factor: 26.132

6.  In vitro antimicrobial effect against Streptococcus pneumoniae of adding rifampin to penicillin, ceftriaxone, or 1-ofloxacin.

Authors:  K P Giron; M E Gross; D M Musher; T W Williams; R A Tharappel
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

7.  Influence of rifampin therapy on serum bactericidal activity in the presence of cloxacillin and vancomycin.

Authors:  A M Mackenzie; N E Macdonald
Journal:  Can J Infect Dis       Date:  1990

8.  Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus.

Authors:  J C Lucet; M Herrmann; P Rohner; R Auckenthaler; F A Waldvogel; D P Lew
Journal:  Antimicrob Agents Chemother       Date:  1990-12       Impact factor: 5.191

Review 9.  Rifampin as adjuvant treatment of Gram-positive bacterial infections: a systematic review of comparative clinical trials.

Authors:  I A Bliziotis; F Ntziora; K R Lawrence; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12       Impact factor: 3.267

10.  Double-blind, placebo-controlled study of oxacillin combined with rifampin in the treatment of staphylococcal infections.

Authors:  P Van der Auwera; J Klastersky; J P Thys; F Meunier-Carpentier; J C Legrand
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.